{"id":"https://openalex.org/W2153305448","doi":"https://doi.org/10.18553/jmcp.2008.14.5.451","title":"Comparison of Cholinesterase Inhibitor Utilization Patterns and Associated Health Care Costs in Alzheimer's Disease","display_name":"Comparison of Cholinesterase Inhibitor Utilization Patterns and Associated Health Care Costs in Alzheimer's Disease","alternate_titles":[],"publication_year":2008,"publication_date":"2008-06-01","ids":{"openalex":"https://openalex.org/W2153305448","doi":"https://doi.org/10.18553/jmcp.2008.14.5.451","mag":"2153305448","pmid":"https://pubmed.ncbi.nlm.nih.gov/18597574","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/10437323"},"language":"en","primary_location":{"id":"doi:10.18553/jmcp.2008.14.5.451","doi":"https://doi.org/10.18553/jmcp.2008.14.5.451","is_oa":false,"landing_page_url":"https://doi.org/10.18553/jmcp.2008.14.5.451","pdf_url":null,"source":{"id":"https://openalex.org/S40961437","display_name":"Journal of Managed Care Pharmacy","issn_l":"1083-4087","issn":["1083-4087","1944-706X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","jufo-1"],"host_organization":"https://openalex.org/P4363609268","host_organization_name":"Academy of Managed Care Pharmacy","host_organization_lineage":["https://openalex.org/P4363609268"],"host_organization_lineage_names":["Academy of Managed Care Pharmacy"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Managed Care Pharmacy","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2153305448"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10437323/pdf/jmcp.2008.14.5.451.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063915748","display_name":"Lisa Mucha","orcid":"https://orcid.org/0000-0002-2435-8133","observed_orcids":["https://orcid.org/0000-0002-2435-8133"]},"institutions":[{"id":"https://openalex.org/I4403928396","display_name":"Wyeth","ror":"https://ror.org/035j24j42","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4403928396"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Lisa Mucha","raw_affiliation_strings":["Global Health Outcomes and Assessment, Wyeth Research, 500 Arcola Rd., Collegeville, PA 19426, USA. muchal@wyeth.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Health Outcomes and Assessment, Wyeth Research, 500 Arcola Rd., Collegeville, PA 19426, USA. muchal@wyeth.com","institution_ids":["https://openalex.org/I4403928396"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Sara Shaohung Wang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Sara Shaohung Wang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045510057","display_name":"Brian J. Cuffel","orcid":"https://orcid.org/0000-0003-0205-0530","observed_orcids":["https://orcid.org/0000-0003-0205-0530"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Brian Cuffel","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077623642","display_name":"Thomas D. McRae","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Thomas McRae","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059037972","display_name":"Tami L. Mark","orcid":"https://orcid.org/0000-0002-5528-881X","observed_orcids":["https://orcid.org/0000-0002-5528-881X"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Tami L. Mark","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5086748089","display_name":"Megan C. del Valle","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Megan del Valle","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":4.7386,"has_fulltext":true,"cited_by_count":76,"citation_normalized_percentile":{"value":0.93884298,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":86,"max":99},"biblio":{"volume":"14","issue":"5","first_page":"451","last_page":"461"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11620","display_name":"Medication Adherence and Compliance","score":0.4343000054359436,"subfield":{"id":"https://openalex.org/subfields/2714","display_name":"Family Practice"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11620","display_name":"Medication Adherence and Compliance","score":0.4343000054359436,"subfield":{"id":"https://openalex.org/subfields/2714","display_name":"Family Practice"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10009","display_name":"Dementia and Cognitive Impairment Research","score":0.2605000138282776,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12023","display_name":"Cholinesterase and Neurodegenerative Diseases","score":0.21719999611377716,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cholinesterase-inhibitors","display_name":"cholinesterase inhibitors","score":0.9279999732971191},{"id":"https://openalex.org/keywords/alzheimer-s-disease","display_name":"Alzheimer's disease","score":1.0},{"id":"https://openalex.org/keywords/treatment-adherence","display_name":"medication adherence","score":0.6349999904632568},{"id":"https://openalex.org/keywords/medication-persistence","display_name":"treatment persistence","score":0.6759999990463257},{"id":"https://openalex.org/keywords/drug-switching","display_name":"drug switching","score":0.7319999933242798},{"id":"https://openalex.org/keywords/medication-possession-ratio","display_name":"medication possession ratio","score":0.8090000152587891},{"id":"https://openalex.org/keywords/health-care-expenditure","display_name":"health care expenditure","score":0.7120000123977661},{"id":"https://openalex.org/keywords/medicare-beneficiaries","display_name":"Medicare beneficiaries","score":0.8690000176429749},{"id":"https://openalex.org/keywords/donepezil","display_name":"donepezil","score":0.9200000166893005},{"id":"https://openalex.org/keywords/galantamine","display_name":"galantamine","score":0.9990000128746033},{"id":"https://openalex.org/keywords/rivastigmine","display_name":"rivastigmine","score":1.0},{"id":"https://openalex.org/keywords/long-term-care","display_name":"long-term care","score":0.5910000205039978},{"id":"https://openalex.org/keywords/nursing-home-care","display_name":"nursing home care","score":0.6620000004768372},{"id":"https://openalex.org/keywords/emergency-department-use","display_name":"emergency department utilization","score":0.4560000002384186},{"id":"https://openalex.org/keywords/comorbidity","display_name":"comorbidities","score":0.6499999761581421},{"id":"https://openalex.org/keywords/older-adults","display_name":"older adults","score":0.5979999899864197},{"id":"https://openalex.org/keywords/prescription-drug-use","display_name":"prescription drug use","score":0.5789999961853027},{"id":"https://openalex.org/keywords/cost-effectiveness-of-treatment","display_name":"treatment cost-effectiveness","score":0.35899999737739563},{"id":"https://openalex.org/keywords/medicare-part-a","display_name":"Medicare Part A","score":0.32499998807907104}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8778092265129089},{"id":"https://openalex.org/C2780904820","wikidata":"https://www.wikidata.org/wiki/Q415081","display_name":"Donepezil","level":4,"score":0.7866271138191223},{"id":"https://openalex.org/C2776332859","wikidata":"https://www.wikidata.org/wiki/Q411887","display_name":"Rivastigmine","level":5,"score":0.776423990726471},{"id":"https://openalex.org/C2779056891","wikidata":"https://www.wikidata.org/wiki/Q412690","display_name":"Galantamine","level":5,"score":0.7440672516822815},{"id":"https://openalex.org/C104863432","wikidata":"https://www.wikidata.org/wiki/Q614304","display_name":"Pharmacy","level":2,"score":0.6357662677764893},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.5147831439971924},{"id":"https://openalex.org/C2779159551","wikidata":"https://www.wikidata.org/wiki/Q1414874","display_name":"Comorbidity","level":2,"score":0.44901084899902344},{"id":"https://openalex.org/C45827449","wikidata":"https://www.wikidata.org/wiki/Q5270338","display_name":"Diagnosis code","level":3,"score":0.444861501455307},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.42965278029441833},{"id":"https://openalex.org/C151956035","wikidata":"https://www.wikidata.org/wiki/Q1132755","display_name":"Logistic regression","level":2,"score":0.4227939248085022},{"id":"https://openalex.org/C149923435","wikidata":"https://www.wikidata.org/wiki/Q37732","display_name":"Demography","level":1,"score":0.3728220462799072},{"id":"https://openalex.org/C512399662","wikidata":"https://www.wikidata.org/wiki/Q3505712","display_name":"Family medicine","level":1,"score":0.3193719983100891},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3105314373970032},{"id":"https://openalex.org/C2779483572","wikidata":"https://www.wikidata.org/wiki/Q83030","display_name":"Dementia","level":3,"score":0.2862563133239746},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.1167629063129425},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.09782424569129944},{"id":"https://openalex.org/C144024400","wikidata":"https://www.wikidata.org/wiki/Q21201","display_name":"Sociology","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000068836","descriptor_name":"Rivastigmine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077265","descriptor_name":"Donepezil","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000544","descriptor_name":"Alzheimer Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D000544","descriptor_name":"Alzheimer Disease","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D002800","descriptor_name":"Cholinesterase Inhibitors","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D002800","descriptor_name":"Cholinesterase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005500","descriptor_name":"Follow-Up Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005702","descriptor_name":"Galantamine","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D005702","descriptor_name":"Galantamine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007189","descriptor_name":"Indans","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D007189","descriptor_name":"Indans","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010349","descriptor_name":"Patient Compliance","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":true},{"descriptor_ui":"D010818","descriptor_name":"Practice Patterns, Physicians'","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015999","descriptor_name":"Multivariate Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016208","descriptor_name":"Databases, Factual","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016527","descriptor_name":"Drug Costs","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017048","descriptor_name":"Health Care Costs","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D048448","descriptor_name":"Phenylcarbamates","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D048448","descriptor_name":"Phenylcarbamates","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.18553/jmcp.2008.14.5.451","doi":"https://doi.org/10.18553/jmcp.2008.14.5.451","is_oa":false,"landing_page_url":"https://doi.org/10.18553/jmcp.2008.14.5.451","pdf_url":null,"source":{"id":"https://openalex.org/S40961437","display_name":"Journal of Managed Care Pharmacy","issn_l":"1083-4087","issn":["1083-4087","1944-706X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","jufo-1"],"host_organization":"https://openalex.org/P4363609268","host_organization_name":"Academy of Managed Care Pharmacy","host_organization_lineage":["https://openalex.org/P4363609268"],"host_organization_lineage_names":["Academy of Managed Care Pharmacy"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Managed Care Pharmacy","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:10437323","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10437323","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10437323/pdf/jmcp.2008.14.5.451.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"J Manag Care Pharm","raw_type":"Text"},{"id":"pmid:18597574","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18597574","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of managed care pharmacy : JMCP","raw_type":"Comparative Study"}],"best_oa_location":{"id":"pmh:oai:pubmedcentral.nih.gov:10437323","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10437323","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10437323/pdf/jmcp.2008.14.5.451.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"J Manag Care Pharm","raw_type":"Text"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2153305448.pdf","grobid_xml":"https://content.openalex.org/works/W2153305448.grobid-xml"},"referenced_works_count":15,"referenced_works":["https://openalex.org/W34488919","https://openalex.org/W1895538680","https://openalex.org/W1925590521","https://openalex.org/W1984207232","https://openalex.org/W2002957365","https://openalex.org/W2021923166","https://openalex.org/W2023205567","https://openalex.org/W2028401320","https://openalex.org/W2030606692","https://openalex.org/W2031709382","https://openalex.org/W2099833638","https://openalex.org/W2102775471","https://openalex.org/W2114564914","https://openalex.org/W2150409192","https://openalex.org/W2155441883"],"related_works":["https://openalex.org/W2007126312","https://openalex.org/W2019980223","https://openalex.org/W1903310816","https://openalex.org/W2081657026","https://openalex.org/W1986545022","https://openalex.org/W1504437012","https://openalex.org/W2774798040","https://openalex.org/W1983581960","https://openalex.org/W29487239","https://openalex.org/W2615077966"],"abstract_inverted_index":{"BACKGROUND:":[0],"Sustained":[1],"treatment":[2,631,713],"with":[3,41,137,369,425,437,470,634,741,762],"a":[4,191,195,208,272,370,457,635,695],"cholinesterase":[5],"inhibitor":[6],"(ChEI)":[7],"is":[8],"used":[9],"in":[10,24,29,54,152,228,379,567,639,719],"the":[11,14,21,33,65,87,102,236,242,256,323,328,342,352,362,375,380,382,390,450,485,489,528,540,575,612,658,682,700,715,752,773],"management":[12],"of":[13,16,52,58,73,86,89,108,141,154,163,176,204,235,239,341,364,389,405,407,445,460,472,478,487,518,558,569,604,616,629,637,687,699,717],"symptoms":[15],"Alzheimer's":[17],"disease":[18],"(AD).":[19],"However,":[20],"characteristic":[22],"declines":[23],"learning":[25],"and":[26,82,106,198,219,241,261,277,282,291,333,348,397,476,507,536,590,600,674,731],"memory":[27],"seen":[28],"AD":[30,151],"may":[31],"erode":[32],"patient's":[34],"ability":[35],"to":[36,38,68,92,266,361,539,749,755],"adhere":[37],"medication":[39,78,465,702],"regimens":[40],"or":[42,130,161,187,305,503,572,729,744],"without":[43,194],"caregiver":[44],"support.":[45],"OBJECTIVES:":[46],"To":[47],"examine":[48],"differences":[49,227],"by":[50,190,303,314,327],"type":[51,238],"ChEI":[53,196,229,346,384,491,606,624,630,688,757],"(1)":[55,126],"monthly":[56],"prevalence":[57,444],"use,":[59,288],"(2)":[60,132],"nonpersistence,":[61,559],"(3)":[62,178],"switching":[63,519],"from":[64,101,357,751],"index":[66,383,408,464,490,623,701,753],"drug":[67,754],"another":[69,756],"ChEI,":[70],"(4)":[71,199],"number":[72,404],"days":[74,406,571,602,697],"on":[75,158,167,416,466,657,692,707,772],"therapy,":[76,689],"(5)":[77],"possession":[79],"ratio":[80],"(MPR),":[81],"(6)":[83],"an":[84,138],"estimate":[85],"relationship":[88,257],"these":[90],"characteristics":[91,260],"total":[93,324,403,601,640,648],"annual":[94],"health":[95,268,300,642,651,766],"care":[96,269,293,311,643,652,767],"expenditures.":[97],"METHODS:":[98],"Data":[99],"were":[100,355,578,661,746,759,776],"MarketScan":[103],"Medicare":[104,116,304],"Supplemental":[105],"Coordination":[107],"Benefits":[109],"2001-2003":[110],"database,":[111],"which":[112],"comprised":[113],"1.47":[114],"million":[115],"beneficiaries":[117],"during":[118,173,574],"this":[119,358],"3-year":[120],"time":[121,172],"period.":[122],"Inclusion":[123],"criteria":[124,354],"were:":[125],"aged":[127],"65":[128],"years":[129],"older;":[131],"at":[133,170,179,200,365,563],"least":[134,180,201,366,564],"1":[135,181,367,565],"claim":[136,183,368],"International":[139],"Classification":[140],"Diseases,":[142],"Ninth":[143],"Revision,":[144],"Clinical":[145],"Modification":[146],"(ICD-9-CM)":[147],"code":[148],"331.0":[149],"for":[150,184,207,225,232,271,372,387,413,449,494,498,510,513,520,531,543,548,553,580,583,586,592,595,622,654,667,671,677,723,726,734,737,769],"any":[153,162,171,605],"15":[155],"diagnosis":[156,165,371],"fields":[157,166],"outpatient":[159,278],"claims":[160,169],"2":[164],"inpatient":[168,276],"18":[174,210],"months":[175,203,211,711],"observation;":[177],"pharmacy":[182],"donepezil,":[185,581,668],"galantamine,":[186],"rivastigmine":[188,400,426,461,500,514,532,593,678,728],"preceded":[189],"6-month":[192],"period":[193],"claim;":[197],"12":[202,483,710],"follow-up":[205],"data,":[206],"minimum":[209],"continuous":[212],"enrollment.":[213],"Multivariate":[214],"analyses,":[215],"including":[216,275,331],"logistic":[217],"regression":[218],"exponential":[220,249],"conditional":[221,250],"mean":[222,251,646],"models,":[223,252],"tested":[224],"cohort":[226],"utilization,":[230],"controlling":[231,621],"demographics,":[233],"region":[234],"country,":[237],"insurer,":[240],"Charlson":[243],"Comorbidity":[244],"Index":[245],"(comorbid":[246],"diagnoses).":[247],"Using":[248],"we":[253],"also":[254],"examined":[255],"between":[258],"utilization":[259],"all-cause":[262,641,649],"(i.e.,":[263,322],"not":[264,433,608,662,777],"specific":[265],"AD)":[267],"expenditures":[270],"12-month":[273],"period,":[274],"(physician)":[279],"care,":[280,298],"laboratory":[281],"radiology":[283],"services,":[284],"emergency":[285],"room":[286],"(ER)":[287],"prescription":[289],"drugs,":[290],"long-term":[292,310],"services":[294,312],"(e.g.,":[295],"nursing":[296],"home":[297,299],"visits)":[301],"paid":[302,313,335],"private":[306],"insurance,":[307],"but":[308,431],"excluding":[309],"Medicaid.":[315],"Expenditure":[316],"was":[317,385,411,432,447,492,508,523,537,632,721,732],"defined":[318],"as":[319,561],"allowed":[320],"charge":[321],"payment":[325],"received":[326,345,394,399],"service":[329],"provider":[330],"plan":[332],"patient":[334],"amounts.)":[336],"RESULTS:":[337],"More":[338],"than":[339,497,512,527,703,725,736,758],"70%":[340],"patients":[343,377,391,462,474,480,522,533,545,655,690,705,718,760,770],"who":[344,349],"therapy":[347,409,568,720],"otherwise":[350],"met":[351],"inclusion":[353],"excluded":[356],"study":[359],"due":[360],"absence":[363],"AD.":[373],"Of":[374],"3,177":[376],"included":[378],"study,":[381],"donepezil":[386,417,473,495,521,549,587,596,693,724,743],"62.8%":[388],"(n=1,994);":[392],"17.2%":[393],"galantamine":[395,438,479,504,511,544,554,584,672,730,735,745],"(n=546)":[396],"20.1%":[398],"(n=637).":[401],"The":[402,516,645],"dispensed":[410],"greater":[412,696],"those":[414],"starting":[415],"(mean":[418],"[median,":[419],"SD]":[420],"days=226":[421],"[263,":[422],"115])":[423],"compared":[424,436,469],"(206":[427],"[233,":[428],"120],":[429],"P<0.001),":[430],"significantly":[434,524,609,663,778],"different":[435],"(216":[439],"[250,":[440],"119],":[441],"P=0.085).":[442],"Monthly":[443],"use":[446],"similar":[448,538],"3":[451,613,659,774],"drugs":[452],"until":[453],"month":[454,628],"5":[455],"when":[456],"smaller":[458],"proportion":[459,716],"had":[463,694],"hand":[467],"(65.9%)":[468],"72.1%":[471],"(P=0.003)":[475],"72.7%":[477],"(P=0.012).":[481],"At":[482,709],"months,":[484],"likelihood":[486],"receiving":[488],"higher":[493,509,722,733],"(61.1%)":[496],"either":[499,727,742],"(50.1%,":[501],"P<0.001)":[502,535],"(56.4%,":[505],"P=0.048)":[506],"(P=0.030).":[515],"rate":[517,530,542],"lower":[525],"(14.5%)":[526],"switch":[529,541,750],"(21.5%,":[534],"(15.0%,":[546],"P=0.781":[547],"vs.":[550,555,588,597],"galantamine;":[551],"P=0.004":[552],"rivastigmine).":[556,598],"Rates":[557],"measured":[560],"having":[562],"gap":[566],"30":[570],"more":[573],"1-year":[576,650,765],"follow-up,":[577],"63.5%":[579],"63.7%":[582],"(P=0.933":[585],"galantamine),":[589],"68.0%":[591],"(P=0.042":[594],"MPRs":[599],"supply":[603,698],"did":[607,704],"differ":[610],"among":[611],"drugs.":[614],"Results":[615],"multivariate":[617],"models":[618],"showed":[619],"that,":[620],"drug,":[625],"each":[626],"additional":[627],"associated":[633],"reduction":[636],"1%":[638],"costs.":[644],"(SD)":[647],"costs":[653,768],"initiated":[656,691,706,771],"ChEIs":[660,775],"different:":[664],"$12,112":[665],"($16,437)":[666],"$12,137":[669],"($19,154)":[670],"(P=0.978),":[673],"$12,853":[675],"($14,543)":[676],"(P=0.278).":[679],"CONCLUSIONS:":[680],"During":[681],"first":[683],"year":[684],"following":[685,712],"initiation":[686],"rivastigmine.":[708,738,763],"initiation,":[714],"Patients":[739],"treated":[740,761],"less":[747],"likely":[748],"All-cause":[764],"different.":[779]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2153305448","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":3},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":4},{"year":2015,"cited_by_count":5},{"year":2014,"cited_by_count":8},{"year":2013,"cited_by_count":8},{"year":2012,"cited_by_count":3}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
